Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
500 participants
INTERVENTIONAL
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. to investigate the role of early radiation therapy in MRI-determined total resected LGGs;
2. to compare the efficacy of early radiation therapy and that of initial chemotherapy in the LGGs without total resection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
NCT01649830
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
NCT00978458
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686
Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients
NCT01345370
Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
NCT04316039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Total resection with early radiation
Total resected LGGs treated with early radiation
Radiation therapy
Total resection without radiation
Total resected LGGs treated without radiation
No interventions assigned to this group
Residual LGGs with radiation
Residual LGGs treated with early radiation
Radiation therapy
Residual LGGs with chemo
Residual LGGS treated with temozolomide
Temozolomide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiation therapy
Temozolomide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Karnofsky performance status of 60 or more
Exclusion Criteria
* Pregnant or breast feeding
* Diagnosis of another malignancy may exclude subject from study
* Evidence or history of bleeding diathesis
* Evidence or history of hypersensitivity to temozolomide
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Neurosurgery, Sun Yat-sen University Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhongping Chen, M.D., Ph.D.
Role: STUDY_CHAIR
Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YP2008009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.